

iScience, Volume 24

Supplemental information

Multi-omics analysis of respiratory specimen characterizes baseline molecular determinants associated with SARS-CoV-2 outcome

**Jaswinder Singh Maras, Shvetank Sharma, Adil Bhat, Sheetalnath Rooge, Reshu
aggrawal, Ekta Gupta, and Shiv K. Sarin**

1 **Multi-Omics analysis of respiratory specimen characterizes baseline molecular**
 2 **determinants associated with COVID-19 diagnosis and outcome.**


3 Jaswinder Singh Maras^{1*}, Shvetank Sharma¹, Adil Bhat¹, Sheetalnath Rooge², Reshu aggrawal², Ekta
 4 Gupta^{#2} and Shiv K Sarin^{#1, 3*}

5 ¹Department of Molecular and Cellular Medicine, ²Department of Virology and ³Department of
 6 Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.

7

8 **Supplementary Figures:**

9 **Supplementary Figure 1:** Heat map and hierarchical cluster analysis for the viral proteins
 10 identified (p<0.05) show clear segregation of COVID-19 positive (Red bar) from COVID-19
 11 negative (Green bar) patients. The expression is given in the range as Dark brown= upregulated,
 12 Blue= downregulated and white= unregulated. AUROC analysis shows clear distinction of
 13 SARS-COV2 proteins in Positive patients vs. negative patients. **(Related to Figure 1)**



14


SARS-COV2 proteins	AUC	P-value	FC (LOG)
Membrane Glycoprotein	1.00	1.50E-25	11.790
Orf1ab polyprotein	0.99	3.22E-23	11.876
Neucelocapsid Phospoprotein	0.99	5.22E-25	11.783
Chain B SARS-CoV-2 spike glycoprotein	0.99	1.92E-20	11.644
ACE2	0.99	6.77E-23	11.605
Replicase polyprotein 1ab	0.98	1.90E-19	11.588
Protein 9b	0.98	4.17E-24	10.904

15

16

1 **Supplementary Figure 2:** Schema for proteomic sample preparation used in the study. (Related
2 to Figure 1)


3



4

5

6 **Supplementary Figure 3:** Loading plot for the partial least square discriminant analysis
7 showing clear segregation of COVID-19 positive patients from COVID-19 negative and
8 Influenza A H1N1 pdm 2009 positive patients based on proteomic evaluation (Related to
9 Figure 1)




10

11

1 **Supplementary Figure 4:** Total no of proteins differentially regulated and their intersection in
2 COV2+ vs. COV2- and COV2+ vs. Influenza A H1N1 pdm 2009 positive cases is shown. Red
3 denotes proteins up regulated and green denoted the proteins down regulated. **(Related to**
4 **Figure 1)**

5



6

7

8 **Supplementary Figure 5:** Univariate area under the receiver operating curve analysis for MX1
9 (AUC=0.895 CI (0.75-1)) and WARS (AUC=0.948 CI (0.85-1)) **(Related to Figure 1)**

10

11

12

13

14

15


16

17

18


19

20



1 **Supplementary Figure 6:** A hierarchical clustering tree summarizing the correlation among
2 significant pathways upregulated in COVID-19 positive respiratory specimen compared to
3 COVID-19 negative or Influenza A H1N1 pdm 2009 positive cases. Pathways with many shared
4 genes are clustered together. Bigger dots indicate more significant P-values. **(Related to Figure**
5 **1)**


KEGG pathway analysis top 30 FDR 0.05



6

7

1 **Supplementary Figure 7:** A hierarchical clustering tree summarizing the correlation among
 2 significant pathways upregulated in COVID-19 positive respiratory specimen compared to
 3 COVID-19 negative or Influenza A H1N1 pdm 2009 positive cases. Pathways with many shared
 4 genes are clustered together. Bigger dots indicate more significant P-values. (**Related to Figure**
 5 **1)**




6

7

1 **Supplementary Figure 8:** A hierarchical clustering tree summarizing the correlation among
 2 significant pathways downregulated in COVID-19 positive respiratory specimen compared to
 3 COVID-19 negative or Influenza A H1N1 pdm 2009 positive cases. Pathways with many shared
 4 genes are clustered together. Bigger dots indicate more significant P-values. **(Related to Figure**
 5 **1)**


6



7


8

1 **Supplementary Figure 9:** Schema for metaproteomics analysis used in the study (**Related to**
 2 **Figure 1**)




3
4

5 **Supplementary Figure 10:** Alpha diversity index calculated based on the relative abundance of
 6 bacterial peptides identified in COVID-19 positive respiratory specimen as compared to COVID-
 7 19 negative or Influenza A H1N1 pdm 2009 positive cases (p-value $\ast = < 0.05$). (**Related to**
 8 **Figure 1**)



9
10

1 **Supplementary Figure 11:** Linear discriminant analysis showing log2 levels of the identified
 2 bacterial peptides in the respiratory specimen of COVID-19 positive compared to COVID-19
 3 negative (Red) and COVID-19 positive compared to Influenza A H1N1 pdm 2009 positive cases
 4 (Blue). The Linear discriminating analysis showed that COVID-19 positive respiratory
 5 specimen has significantly increased bacterial peptide linked to the (phylum: LCA);
 6 Bacteroidetes: Bacteroidetes Order II. Incertae sedis, Firmicutes: Bacillales, Bacillus subtilis,
 7 Lactobacillus plantarum, Proteobacteria: Burkholderiales, Enterobacterales, Klebsiella
 8 pneumonia and others, Tenericutes: Mycoplasma genitalium, Mycoplasma mobile and others
 9 whereas bacterial peptide linked to Actinobacteria: Corynebacteriales, Streptomycetales,
 10 Firmicutes: Bacillus subtilis, Lysinibacillus, Lactobacillus salivarius and others, Proteobacteria :
 11 Gamma proteobacteria, pseudomonadales and others and Tenericutes:Mycoplasmatales were
 12 significantly reduced as compared to other groups (**Related to Figure 1**)




13


14

15

1 **Supplementary Figure 12:** Random forest analysis and mean decrease in accuracy plot showing
 2 the mean decrease in accuracy of the metaproteome along with their expression status Red=
 3 upregulated and Green= downregulated and yellow= unchanged in COVID-19 positive as
 4 compared to COVID-19 negative or Influenza A H1N1 pdm 2009 positive cases patients
 5 **(Related to Figure 1)**



6
 7 **Supplementary Figure 13:** Area under the receiver operating curve analysis for Variable 80 and
 8 Variable 30 together show AUC=1 CI (1-1) p<0.05 and Prediction class probability with a
 9 predictive accuracy of 100%. **(Related to Figure 1)**



10
 11


1 **Supplementary Figure 14:** Enzyme coded by the bacterial peptides and their abundance in
 2 COVID-19 positive compared to COVID-19 negative and COVID-19 positive compared to
 3 Influenza A H1N1 pdm 2009 positive cases (Red shows upregulated and Green shows down
 4 regulated). Functionality analysis of the COVID-19 positive respiratory microbiome highlighted
 5 significant increase in enzymes linked to pantothenate and CoA biosynthesis in actinobacteria
 6 (EC1.1.1.86), aminoacyl-trna biosynthesis and terpenoid backbone biosynthesis in firmicutes
 7 (EC6.1.1.20, EC1.17.7.4), amino-nucleotide sugar metabolism, peptidoglycan biosynthesis, fatty
 8 acid biosynthesis and glycerophospholipid metabolism, energy metabolism and others
 9 (EC2.3.1.157, EC2.4.1.227, EC1.1.1.37, EC2.3.1.15, EC2.1.3.15, EC7.1.2.2, EC4.1.1.20) in
 10 proteobacteria and others showing a clear indication of bacterial pathogenic thrust in presence of
 11 CoV-2. Whereas enzyme linked to nicotinate and nicotinamide metabolism (EC2.7.1.23) in
 12 actinobacteria, arginine biosynthesis (EC3.5.1.5) in firmicutes, and Aminoacyl-tRNA
 13 biosynthesis linked to aspartate and asparagine metabolism in tenericute were decreased
 14 ((Related to Figure 1)

Taxa	COV2+ vs. COV- COV2+ vs. H1N1	Phylum: LCA:EC:Enzyme
Actinobacteria	Red	Actinobacteria:Actinobacteria:1.1.1.86 :Ketol-acid reductoisomerase (NADP(+))
	Green	Actinobacteria:Streptomyces:2.7.1.23 :NAD(+) kinase
Bacteria	Green	:Bacteria:4.1.1.3 :Transferred entry: 4.1.1.112
	Green	:Bacteria:5.1.3.14 :UDP-N-acetylglucosamine 2-epimerase (non-hydrolyzing)
	Red	:Bacteria:3.6.3.- :Acting on acid anhydrides; catalyzing transmembrane movement of substances
	Red	:Bacteria:2.3.1.234 :N(6)-L-threonylcarbamoyladenine synthase
	Red	:Bacteria:2.3.3.13 :2-isopropylmalate synthase
	Green	:Bacteria:2.7.4.25 :(d)CMP kinase
	Green	:Bacteria:3.4.24.- :Metalloendopeptidases
	Green	:Bacteria:2.7.7.6 :DNA-directed RNA polymerase
	Green	:Bacteria:3.4.24.- :Metalloendopeptidases
	Bacteroidetes	Red
Firmicutes	Red	Firmicutes:Lactobacillus plantarum:6.1.1.20 :Phenylalanine--tRNA ligase
	Red	Firmicutes:Bacillales:1.17.7.4 :4-hydroxy-3-methylbut-2-enyl diphosphate reductase
	Green	Firmicutes:Lysinibacillus:3.5.1.5 :Urease
Proteobacteria	Green	Firmicutes:Bacillus:2.3.1.- :Transferring groups other than amino-acyl groups
	Red	Proteobacteria:Acidiphilium cryptum:2.3.1.157 :Glucosamine-1-phosphate N-acetyltransferase
	Red	Proteobacteria:Geobacter:2.4.1.227 :Undecaprenyldiphospho-muramoylpentapeptide beta-Nacetylglucosaminyltransferase
	Red	Proteobacteria:Klebsiella pneumoniae:1.1.1.37 :Malate dehydrogenase
	Red	Proteobacteria:Enterobacterales:2.3.1.15 :Glycerol-3-phosphate 1-O-acyltransferase
	Red	Proteobacteria:Burkholderia:5.2.1.8 :Peptidylprolyl isomerase
	Red	Proteobacteria:[Mannheimia] succiniciproducens:2.1.3.15 :Acetyl-CoA carboxytransferase
	Red	Proteobacteria:Desulfatibacillum:7.1.2.2 :H(+)-transporting two-sector ATPase
Tenericutes	Green	Proteobacteria:Pseudomonas syringae group:4.1.1.20 :Diaminopimelate decarboxylase
	Green	Proteobacteria:Candidatus Baumannia cicadellinicola::
	Red	Tenericutes:Mycoplasma:3.6.1.- :In phosphorus-containing anhydrides
	Red	Tenericutes:Ureaplasma:3.6.-.- :Acting on acid anhydrides
Tenericutes	Green	Tenericutes:Mycoplasma genitalium:6.3.5.7 :Glutaminyl-tRNA synthase (glutamine-hydrolyzing)
	Green	Tenericutes:Mycoplasma genitalium:6.1.1.22 :Asparagine--tRNA ligase


15

16

1 **Supplementary Figure 15:** Schema for metabolomics analysis used in the study (**Related to**
 2 **Figure 2**)




3
 4 **Supplementary Figure 16:** Total no of metabolites differentially regulated and their intersection
 5 in COV2+ vs. COV2- and COV2+ vs. Influenza A H1N1 pdm 2009 positive cases is shown. Red
 6 denotes proteins up regulated and green denoted the proteins down regulated. (**Related to Figure**
 7 **2**)



1 **Supplementary Figure 17:** Loading plot for the partial least square discriminant analysis
2 showing clear segregation of COVID-19 positive patients from COVID-19 negative and
3 Influenza A H1N1 pdm 2009 positive cases patients based on metabolomics evaluation (**Related**
4 **to Figure 2**)

5




6

7


8 **Supplementary Figure 18:** Univariate area under the receiver operating curve analysis for N-
9 Acetylserotonin(AUC=0.99 CI (0.975-1)) and Azelaic acid (AUC=0.941 CI (0.85-1)) (**Related**
10 **to Figure 2**)

11




12


1 **Supplementary Figure 19:** Correlation plot showing top 54 proteins and metabolites which
 2 showed significant correlation with the CT values of COVID-19 positive patients. Green
 3 highlight on the molecules are positively correlated to the CT values and Red color highlight on
 4 the molecules denotes negative correlation with the CT values (RT-PCR). **(Related to Figure 3)**



5
 6 **Supplementary Figure 20:** BTM enrichment analysis of respiratory proteome identifies
 7 immune clusters represented as web plot showing the number of proteins present in each module,
 8 red= upregulated in COVID-19 respiratory specimen and green= downregulated in COVID-19
 9 respiratory specimen. **(Related to Figure 3)**



1 **Supplementary Figure 21:** Volcano plot showing differentially expressed multi-omics data in
 2 asymptomatic COVID-19 as compared to symptomatic COVID-19 respiratory specimen. Pink
 3 dots are significant ($p < 0.05$, $FC > 1.5$), Partial least square discriminant analysis showing clear
 4 segregation of symptomatic COVID-19 patients (Red dots) from asymptomatic COVID-19
 5 patients (Green dots) based on Multi-omics estimations, Heat map and hierarchical cluster
 6 analysis of the multi-omics identified ($p < 0.05$) show clear segregation of COVID-19
 7 symptomatic (Red bar) from asymptomatic COVID-19 (Green bar) patients. The expression is
 8 given in the range as Dark brown= upregulated, Blue= downregulated and white= unregulated.
 9 **(Related to Figure 3)**



10


11 **Supplementary Figure 22:** Area under the receiver operating curve analysis along with fold
 12 change and significance of bio-molecules capable of segregating COVID-19 symptomatic from
 13 asymptomatic COVID-19 patients. **(Related to Figure 3)**

Parameters	AUC	Pval	FC (log) Symptomatic vs. Asymptomatic
Proteobacteria_Enterobacterales_Klebsiell a_pneumoniae_VAVLXAAGGIQALALLK	0.845	0.013	2.33
CTBP2	0.774	0.045	1.59
C04453	0.917	0.006	0.61
C00386	0.714	0.029	-0.65
C00555	0.786	0.036	-1.04
C02571	0.845	0.007	-1.13
C04840	0.821	0.029	-1.39
PSME2	0.810	0.044	-1.73
Proteobacteria_Desulfobacterales_Desulfa tibacillum_DQEGQDVLIFIDNIFR	0.821	0.013	-1.81
COPE	0.726	0.050	-2.19
AKR1A1	0.798	0.032	-3.05

14

1 **Supplementary Figure 23:** Permutation statistical analysis for prediction class probability of
2 MX1 (1000 permutation) show $p < 0.01$. **(Related to Figure 4)**


3



4

5 **Supplementary Figure 24:** Permutation statistical analysis for prediction class probability of
6 MX1 and WARS (1000 permutation) together show $p < 0.01$. **(Related to Figure 4)**

7




8

9

10

1 **Supplementary Figure 25: KEGG pathway enrichment analysis for proteins upregulated in the**
 2 **respiratory specimen of COVID-19 positive patients as compared to COVID-19 negative**
 3 **patients showing significant enrichment of proteins lined to Glycolysis/ Gluconeogenesis.**
 4 **(Related to Figure 1)**



5
 6

1

2 **Supplementary Figure 26:** Correlation of MX1 and WARS Elisa levels with the respiratory rate
3 and SOFA score of COVID 19 patients. **(Related to Figure 4)**

4

Parameters	MX1	WARS
Respiratory Rate	r=0.65, p=0.0024	r=0.48, p=0.041
SOFA Score	r=0.71, p=0.0001	r=0.53, p=0.047


5

6

7 Supplementary figure 27: **(Related to Figure 4)**

8 Correlation Plot OF MX1 and WARS with MIF, VEGF-A, IL-6 and Immune interferon gamma

9 Red documents p<0.05 and R>0.5



10


11

1


2

3 **Supplement Figure 28 (Related to Figure 4)**

4 Quantitative assessment of MX1 and WARS in the respiratory specimen of the test cohort
5 (n=200; severe infection: 50, non-severe infection: 50 and RTPCR based COVID-19 positive
6 specimen. COVID-19 positive specimen show significant increase in MX1 and WARS levels in
7 COVID-19 positive particularly in patients with severe infection as compared to COVID-19
8 negative (upper panel; FC> 2, p<0.05). Lower panel documents AUROC value for prediction of
9 COV2+ for MX1 and WARS in COVID-19 patients.



10



11

12

13


1 **Supplementary Figure 29 (Related to Figure 4)**

2

3 Combined AUROC of MX1 and WARS and 2000 samples bootstrapping analysis in the test
4 cohort (n=200; severe infection: 50, non-severe infection: 50 and RTPCR based COVID-19
5 positive specimen).

6

7



8

9

10

11

12

